A Phase 2, Randomized, Dose-Ranging Study to Assess the Safety and Anti-Cytomegalovirus Activity of Maribavir versus Valganciclovir for the Treatment of CMV Infections in Transplant Recipients Who Do Not Have CMV Organ Disease

Trial Profile

A Phase 2, Randomized, Dose-Ranging Study to Assess the Safety and Anti-Cytomegalovirus Activity of Maribavir versus Valganciclovir for the Treatment of CMV Infections in Transplant Recipients Who Do Not Have CMV Organ Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Maribavir (Primary) ; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Shire ViroPharma
  • Most Recent Events

    • 15 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database.
    • 27 Jun 2013 Preliminary results of pooled dosages reported in ViroPharma media release.
    • 26 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top